Skip to main content
Clinical Trials/NCT02108171
NCT02108171
Completed
Not Applicable

A Randomised Controlled Trial of Intranasal Dexmedetomidine as Premedication for Suspension Laryngoscopy

Guangzhou First People's Hospital1 site in 1 country81 target enrollmentMarch 2014

Overview

Phase
Not Applicable
Intervention
Dexmedetomidine
Conditions
Benign Neoplasm of Vocal Fold - Glottis
Sponsor
Guangzhou First People's Hospital
Enrollment
81
Locations
1
Primary Endpoint
Extubation Time After Intranasal Dexmedetomidine Premedication
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Most patients with preoperative varying degrees of stress, anxiety, which makes the stress response in patients and affect the normal conduct of anesthesia and surgery.The sympathetic system hyperexcitability prone to cause adverse cardiovascular events and affect postoperative recovery. However, phenobarbital, as the traditional premedication, has less sedative, weak anxiolytic and other shortcomings. Midazolam accompanied by inhibition of respiration,excessive sedation, easily induced delirium,prolonged recovery time and so on. Dexmedetomidine is a highly selective α2-adrenergic receptor agonist, it has sedative, anxiolytic, no inhibition of respiration, and also colorless, odorless, non-mucosal stimulation, nasal drip ease of administration, patient acceptance, comfortable. Therefore, dexmedetomidine as premedication has certain advantages. The purpose of this research is to study sedative effect, safety and the impact of anesthesia recovery period of intranasal dexmedetomidine premedication for suspension laryngoscopy.

Detailed Description

All patients received intranasal dexmedetomidine (1μg.kg-1) or placebo at approximately 45 min before induction of anesthesia.The study drug was prepared in a 1-ml syringe.An equal volume of dexmedetomidine or placebo was dropped into each nostril by a blinded research assistant in the supine position.Automatic sphygmomanometer measure blood pressure.Oxygen saturation and heart rate were measured by a pulse oximeter. Respiratory rate, sedation score and anxiety levels regularly assessed. Patients with general anesthesia, suspension laryngoscopy surgery and postoperative care, standard monitoring are unified.

Registry
clinicaltrials.gov
Start Date
March 2014
End Date
July 2014
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Guangzhou First People's Hospital
Responsible Party
Principal Investigator
Principal Investigator

Xiangcai Ruan, MD, PhD, Vice-Director in Dept Anesth & Pain

Vice Chair

Guangzhou First People's Hospital

Eligibility Criteria

Inclusion Criteria

  • Surgery:The laryngoscope vocal polyp excision
  • Aged 18 to 60 years old
  • Body mass index (BMI) \< 30 kg/m2
  • American society of Anesthesiologist (ASA) I -II

Exclusion Criteria

  • The investigator refused to participate
  • Known allergy or hypersensitive reaction to dexmedetomidine or anesthetic
  • With previous history of heart disease
  • Pregnant women; no reliable contraceptive measures in postmenopausal women
  • Preoperative heart rate less than 45bpm; Ⅱ or Ⅲ degree atrioventricular block; ischemic heart disease
  • Taking antihypertensive drugs such as methyldopa, clonidine and other α2 receptor agonist
  • Sleep apnea syndrome
  • Liver and kidney dysfunction
  • Known to suffer from mental illness
  • Long-term use of sedatives and analgesics in patients

Arms & Interventions

dexmedetomidine

intranasal dexmedetomidine

Intervention: Dexmedetomidine

placebo

intranasal saline

Intervention: placebo

Outcomes

Primary Outcomes

Extubation Time After Intranasal Dexmedetomidine Premedication

Time Frame: 1 days

The times from stopping anesthetic infusions to adequate ventilation, consciousness and extubation after intranasal dexmedetomidine or placebo administration

Secondary Outcomes

  • Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine(1 day)
  • Modified OAA/S Scores of Patients Receiving Intranasal Placebo or Dexmedetomidine(1 days)
  • Number of Participants With Anxiety Score >2(1 day)
  • Anxiety Score of Patients Receiving Intranasal Placebo or Dexmedetomidine(1 day)
  • Systolic Blood Pressure(SBP)of Patients Receiving Intranasal Placebo or Dexmedetomidine(1 day)
  • Number of Participants With Satisfaction Score <2(1 day)
  • Perioperative Bradycardia Episodes(1 day)
  • Perioperative Tachycardia Episodes(1 day)
  • Perioperative Hypotension Episodes(1 day)
  • Perioperative Hypertonsion Episodes(1 day)

Study Sites (1)

Loading locations...

Similar Trials